Publications by authors named "M P Ghazarian"
Article Synopsis
- - Resistance to antimicrobial agents poses a significant global health threat, prompting the need for new treatment strategies targeting pathogens’ ability to manipulate host defenses, especially through epigenetic modification.
- - Legionella pneumophila, a Gram-negative intracellular bacterium, releases a specific methyltransferase named RomA that alters host epigenetic regulation by methylating H3 K14, helping the pathogen evade immune responses.
- - To inhibit RomA's activity, researchers developed a high-content imaging assay to screen chemical compounds targeting methyltransferases, successfully identifying potential inhibitors from an initial library of 477 compounds.
Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair.
Semin Cancer Biol
January 2024
Hypoxia is a hallmark feature of the tumor microenvironment which can promote mutagenesis and instability. This increase in mutational burden occurs as a result of the downregulation of DNA repair systems. Deficits in the DNA damage response can be exploited to induce cytotoxicity and treat advanced stage cancers.
View Article and Find Full Text PDFThe success of mRNA-based vaccines during the Covid-19 pandemic has highlighted the value of this new platform for vaccine development against infectious disease. However, the CD8 T cell response remains modest with mRNA vaccines, and these do not induce mucosal immunity, which would be needed to prevent viral spread in the healthy population. To address this drawback, we developed a dendritic cell targeting mucosal vaccination vector, the homopentameric STxB.
View Article and Find Full Text PDFObjective: To describe the surgical and oncologic outcomes in surgically treated oldest old women (≥80 years) with endometrioid endometrial cancer as a function of their comorbidities.
Methods: In this retrospective cohort study, patients aged 80-99 years who underwent surgical management of stage I endometrioid endometrial cancer between 2006 and 2018 were included. Low- and high-intermediate risk disease was defined using the Gynecologic Oncology Group-99 criteria.